Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

뉴스 본문을 불러오고 있어요.

Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma | 웨이프 WAPE

Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

기사 요약

관련 종목

댓글 —